Trial Profile
Multicenter Safety, Feasibility and Pharmacokinetic Phase I Trial of ModraDoc006/r in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Docetaxel/ritonavir (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Modra Pharmaceuticals
- 03 Nov 2020 Status changed from active, no longer recruiting to completed.
- 15 Feb 2020 Safety and efficacy results (n=20) presented at the 2020 Genitourinary Cancers Symposium.
- 25 Mar 2019 Status changed from recruiting to active, no longer recruiting.